| Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals F Asnicar, SE Berry, AM Valdes, LH Nguyen, G Piccinno, DA Drew, ... Nature medicine 27 (2), 321-332, 2021 | 595 | 2021 |
| Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4 A Blanco-Míguez, F Beghini, F Cumbo, LJ McIver, KN Thompson, M Zolfo, ... Nature Biotechnology 41 (11), 1633-1644, 2023 | 235 | 2023 |
| Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature medicine 29 (8), 2121-2132, 2023 | 65 | 2023 |
| High intake of vegetables is linked to lower white blood cell profile and the effect is mediated by the gut microbiome C Menni, P Louca, SE Berry, A Vijay, S Astbury, ER Leeming, R Gibson, ... BMC medicine 19, 1-10, 2021 | 49 | 2021 |
| MetaPhlAn 4 profiling of unknown species-level genome bins improves the characterization of diet-associated microbiome changes in mice P Manghi, A Blanco-Míguez, S Manara, A NabiNejad, F Cumbo, F Beghini, ... Cell Reports 42 (5), 2023 | 4 | 2023 |
| 1452MO Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC) CAC Silva, G Piccinno, L Cerbone, V Iebba, E Colomba, R Flippot, C Sow, ... Annals of Oncology 33, S1208, 2022 | 2 | 2022 |
| Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial C Alves Costa Silva, G Piccinno, D Suissa, M Bourgin, G Schreibelt, ... Nature Communications 15 (1), 1633, 2024 | 1 | 2024 |
| Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature Medicine 30 (2), 604-604, 2024 | 1 | 2024 |
| Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational … F Marmorino, G Piccinno, D Rossini, F Ghelardi, S Murgioni, L Salvatore, ... Journal of Clinical Oncology 41 (16_suppl), 3534-3534, 2023 | 1 | 2023 |
| The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups and correlates with gut microbiota (GM) in patients with advanced renal cell carcinoma (RCC). CAC Silva, S Zoppi, A Reni, G Piccinno, I Lahmar, L Cerbone, ... Journal of Clinical Oncology 41 (6_suppl), 719-719, 2023 | 1 | 2023 |
| 863P Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint … D Galizia, S Minei, A Abbona, M Paccagnella, G Piccinno, A Polidori, ... Annals of Oncology 34, S560, 2023 | | 2023 |
| SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational … F Marmorino, G Piccinno, D Rossini, F Ghelardi, S Murgioni, L Salvatore, ... Annals of Oncology 34, S171, 2023 | | 2023 |
| Microbiota-associated metabolic reprograming influenced clinical outcome in the randomized dendritic cell-based clinical trial in stage III melanoma C ALVES-COSTA-SILVA, M Bourgin, G Piccinno, G Schreibelt, S Durand, ... | | 2023 |
